128 related articles for article (PubMed ID: 3656356)
1. Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (+/-)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)- methoxy]methyl]ethoxy]hexanoic acids.
Manley PW; Tuffin DP; Allanson NM; Buckle PE; Lad N; Lai SM; Lunt DO; Porter RA; Wade PJ
J Med Chem; 1987 Oct; 30(10):1812-8. PubMed ID: 3656356
[TBL] [Abstract][Full Text] [Related]
2. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
Maguire ED; Wallis RB
Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
[TBL] [Abstract][Full Text] [Related]
3. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
Mallarkey G; Smith GM
Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
[TBL] [Abstract][Full Text] [Related]
5. [(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors.
Martinez GR; Walker KA; Hirschfeld DR; Maloney PJ; Yang DS; Rosenkranz RP
J Med Chem; 1989 Apr; 32(4):890-7. PubMed ID: 2704033
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors.
Manley PW; Allanson NM; Booth RF; Buckle PE; Kuzniar EJ; Lad N; Lai SM; Lunt DO; Tuffin DP
J Med Chem; 1987 Sep; 30(9):1588-95. PubMed ID: 3305945
[TBL] [Abstract][Full Text] [Related]
7. Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues.
Cross PE; Dickinson RP; Parry MJ; Randall MJ
J Med Chem; 1986 Mar; 29(3):342-6. PubMed ID: 3081722
[TBL] [Abstract][Full Text] [Related]
8. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of ibuprofen, indomethacin, and meclofenamate on prostaglandin endoperoxide H2 metabolism.
Mayeux PR; Kadowitz PJ; McNamara DB
Mol Cell Biochem; 1989 May; 87(1):41-6. PubMed ID: 2505061
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a bidirectional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery.
Mayeux PR; Kadowitz PJ; McNamara DB
Biochim Biophys Acta; 1989 Mar; 1011(1):18-24. PubMed ID: 2493809
[TBL] [Abstract][Full Text] [Related]
11. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
12. [Synthesis and platelet aggregation inhibitory activity of analogues of 4-([2-(1H-imidazol-1-yl)-1-(4-substituted-phenyl)ethoxy]methyl)benzoic acids].
Wu QY; Yang JQ
Yao Xue Xue Bao; 1991; 26(10):741-6. PubMed ID: 1823715
[TBL] [Abstract][Full Text] [Related]
13. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
Hornberger WB; Patscheke H
Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
Dickinson RP; Dack KN; Long CJ; Steele J
J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
[TBL] [Abstract][Full Text] [Related]
17. Transformations of prostaglandin H2 in the cat brain.
Bishai I; Coceani F
Biochim Biophys Acta; 1981 Apr; 664(1):1-9. PubMed ID: 6894549
[TBL] [Abstract][Full Text] [Related]
18. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
19. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man.
MacNab MW; Foltz EL; Graves BS; Rinehart RK; Tripp SL; Feliciano NR; Sen S
J Clin Pharmacol; 1984; 24(2-3):76-83. PubMed ID: 6371062
[TBL] [Abstract][Full Text] [Related]
20. Effects of a thromboxane synthetase inhibitor on platelet function; possible risks of use in pregnancy.
Sullivan MH; Ahmed Y; Elder MG
Prostaglandins; 1993 Jul; 46(1):21-6. PubMed ID: 8378539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
